Economic burden of Parkinson's disease in a developing country: A retrospective cost analysis in Shanghai, China
Economic burden of Parkinson's disease in a developing country: A retrospective cost analysis in Shanghai, China
复制标题
DOI：
10.1002/mds.20999
复制
发表时间：
2006-09-01
影响因子：
8.6
通讯作者：
Chen, Sheng-Di
中科院分区：
文献类型：
--
作者：
Wang, Gang;Cheng, Qi;Chen, Sheng-Di
我们调查了中国上海帕金森氏病（PD）患者的经济成本，这可以作为未来评估的基线。对190例患者进行为期1年的访谈。每位患者每年的直接医疗费用平均约为人民币4,305元（合519美元或410欧元），其中药品（2,677元）是主要的成本组成部分。非医疗直接成本远低于直接医疗成本，平均约为人民币3,301元（398美元或314欧元）。生产力损失造成的成本平均约为每位患者每年人民币73元（8.8美元或7.0欧元）。综上所述，我们系列产品的PD年平均成本约为7679元人民币（925美元或731欧元），这些成本约占平均年收入的一半。总费用与疾病严重程度和门诊就诊频率显著相关。此外，左旋多巴等效剂量（LED）和服药次数也与药费密切相关。结果表明，我国帕金森病患者的经济负担较重。(c) 2006年运动障碍协会。
We investigated economic costs from patients with Parkinson's disease (PD) in Shanghai, China, which could be used as a baseline for future evaluations. Data were collected from 190 patients by interview during 1-year period. Direct medical care costs averaged approximately Chinese yuan, ren-minbi (RMB) 4,305 (USD 519, or EUR 410) per year per patient, of which drugs (RMB 2,677) accounted for the major costly component. Nonmedical direct costs were much less than direct health care costs, averaging approximately RMB 3,301 (USD 398, or EUR 314). Costs due to loss of productivity averaged approximately RMB 73 (USD 8.8, or EUR 7.0) per patient per year. Taken together, the overall mean annual cost for PD in our series was approximately RMB 7,679 (USD 925, or EUR 731), and these costs accounted for around half of the mean annual income. Total cost was significantly associated with the disease severity and the frequency of outpatient visits. In addition, levodopa equivalent dose (LED) and the number of drugs being taken were also closely related with the drug cost. The results indicate that the economic burden of Chinese PD patients is heavy. (c) 2006 Movement Disorder Society.